AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00598559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: Arm 1: 1 g IV Acetaminophen every 6 hours administered for five days. Arm 2: 650 mg IV Acetaminophen every 4 hours administered for five days. Arm 3: The standard of care treatments were defined as any medication the investigator deemed appropriate to treat the subject, including products containing acetaminophen but excluding IV acetaminophen.
Study NCT00598559 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IV Acetaminophen
Description: Arm 1: 1 g IV Acetaminophen every 6 hours administered for five days. Arm 2: 650 mg IV Acetaminophen every 4 hours administered for five days. Arm 3: The standard of care treatments were defined as any medication the investigator deemed appropriate to treat the subject, including products containing acetaminophen but excluding IV acetaminophen.
Study NCT03480711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SST in group (A)
Description: group (A) single surgeon, using retrobulbar anaesthesia with 2% lidocaine, will be performed in all surgeries. Following insertion of a lid speculum, a 10/0 silk bridle suture is inserted at superior limbus if required. In group (A) a conjunctival incision is made at the limbus to create a fornix-based conjunctival flap. A half thickness scleral flap (4 × 4 mm) are created and dissected into the clear cornea. A cellulose microsponge soaked in 0.3 mg/ml MMC solution (Mitomycin-C) is applied to the under surface of the scleral flap over a wide posterior area for 2 ml
Study NCT03480711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trabeculectomy with ESST in group (B)
Description: group (B), another longitudinal scleral groove will be created in the center of the deep scleral bed area measured about 1.5 × 6 mm.In both groups, standard trabeculectomy of equal size (two bites aside) is created by a Kelly punch ( 1 mm)
Study NCT02261428 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter Tiemann
Description: We tested the ability of Tiemann catheter to access trachea in order to aspirate bronchial secretions in ICU patients
Study NCT02261428 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suction catheter
Description: We tested the ability of Suction catheter to access trachea in order to aspirate bronchial secretions in ICU patients
Study NCT04675177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polidocanol foam sclerotherapy
Description: i. Patients underwent preparation, two hours before the intervention, with cleaning enema (Disodium phosphate). No antibiotic prophylaxis was prescribed.~ii. Preparation of the polidocanol (Aethoxysklerol 3%) foam according to Tessari technique immediately before application, so that the microbubbles of the foam did not disintegrate; iii. The procedure was performed in the medical office. Application according to the Blanchard technique through a disposable transparent anoscope, in jackknife position, using a 20mL disposable syringe of the mixture (polidocanol + air) and a reusable 10 cm syringe extender adapted to an intravenous needle; iv. Patients were treated in a maximum of 3 sessions, at 3 weeks intervals; v. Maximum dose per treatment session of 20mL of mixture of 4mL of polidocanol 3% with 16mL of air; i. In each session, the sclerosant was injected in one or more hemorroidary cushion;
Study NCT04675177 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Doppler-guided hemorrhoidal artery ligation
Description: i. Patients underwent preparation with cleaning enema (Disodium phosphate). No antibiotic prophylaxis was prescribed.~ii. The procedure was performed in the operating room of an outpatient surgery unit, under regional anestesia.~iii. A proctoscope with a Doppler transducer in its tip was introduced inside the anal canal to search for the superior rectal artery.~iv. Each branch was ligated with suture above the dentate line. The device was rotated slowly in clockwise direction to locate further arteries at that level.~v. Rectoanal repair consisted in a continuous running suture was applied longitudinally just over every prolapsed hemorrhoid.
Study NCT03145532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS plus robotic training
Description: Children will first receive 20 min of tDCS (real or sham, see Arms), then will receive 1 hr of upper limb robotic therapy in which the child will use their impaired arm and hand to move a joystick controlling a cursor to a set of targets on a video screen in front of the child.
Study NCT03145532 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: tDCS plus robotic training
Description: Children will first receive 20 min of tDCS (real or sham, see Arms), then will receive 1 hr of upper limb robotic therapy in which the child will use their impaired arm and hand to move a joystick controlling a cursor to a set of targets on a video screen in front of the child.
Study NCT01880333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Atkin Diet
Description: Eligible children will be started on Modified Atkins diet with help of trained dietician. Carbohydrates intake will be restricted to 5 grams/ day in children\<18 mo and 10grams/day in children 18mo- 3 years.Carbohydrate values of various food items will be explained in detail. Fats (e.g. cream, butter, oils, and ghee) will be encouraged. Proteins (cheese, fish, eggs, chicken, and soya products) will be unrestricted. Calcium and multivitamin supplementation will be done. Syrups will be restricted. Clear carbohydrates free fluids- will not be restricted. Medications will be changed to carbohydrate free preparations, wherever available. Diary of events will be recorded including seizure frequency and any adverse or positive effect. Urine ketones chart will be maintained.
Study NCT01811446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muscle Activation with Niveus and Intelect Devices
Description: Subjects will receive muscle activation technology from the Niveus device on one leg and from the Intelect (commercially-available third-party) device on the other. The order of use and the leg applied to will be randomized.
Study NCT00133718 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Combined lifestyle intervention and optimisation of pharmacological treatment
Description: 1. 6 months non-pharmacological treatment, 18 months with polypharmacy for glucose control (metformin, repaglinide/glimepiride, pioglitazone or insulin)~2. standard care
Study NCT01053273 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal Epidural Injection
Description: Group I will receive caudal epidural injections with catheterization up to S3 with local anesthetic, steroids, and 0.9% sodium chloride solution
Study NCT01053273 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous adhesiolysis
Description: Group II will receive percutaneous adhesiolysis with targeted delivery of lidocaine, 10% hypertonic sodium chloride solution, and non-particulate betamethasone.
Study NCT02355743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rtPA lock therapy
Description: rtPA 2 mg/2 ml, or 110% of the volume of the catheter lumen if less than 2 mL, administered locally in a volume to fill the lumen (dead space) of the CVAD, once weekly for a total of 24 weeks. rtPA will be given as research intervention as lock therapy in that it will dwell within the catheter of the CVAD for a specified duration of time and then be removed (aspirated); in this setting the medication is not given to the patient as a flush, i.e. in systemic fashion.
Study NCT02961530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isokinetic eccentric exercises
Description: The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~15 days after partial menisectomy, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isokinetic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours.
Study NCT02961530 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic eccentric exercises
Description: The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~15 days after partial menisectomy, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isotonic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours.
Study NCT01992679 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: The BWSTT program will consist of biweekly training sessions for 20 weeks. Per neurorecovery network guidelines, each training session will include a minimum of 20 minutes of locomotor training and 20 minutes of balance training. Training will take place on a Therastride which consists of a treadmill with an air pressure powered pulley system connected to a harness system. The locomotor training strategy focuses on proper gait mechanics, including weight bearing, shifting and maintaining body positioning. Manipulating the participant's legs is done in such a way as to provide appropriate sensory-motor cues that facilitate the development and refinement of walking pattern.
Study NCT03804710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Developmental moisturizing cream 1
Description: Participants will topically apply developmental moisturizing cream 1
Study NCT03804710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Developmental moisturizing cream 2
Description: Participants will topically apply developmental moisturizing cream 2
Study NCT03804710 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard cleanser soap
Description: Participants will cleanse the entire face and both lower legs (between the knees and the ankles)with simple pure soap
Study NCT03403868 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: conductance catheter
Description: pressure volume loops are assessed via a special catheter (Conductance catheter)
Study NCT03209323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroencephalography (EEG)
Description: Four EEG channels were recorded using electrode positions as defined in the International 10-20 System with Ag/AgCl2 cup electrodes (Spes Medica) attached to the scalp with EC2 Electrode Cream (Grass Technologies). The impedance was set below 1 k, and the electrodes were attached to module S/5 E-EEG of the anaesthetic monitor S/5 (GE Healthcare).
Study NCT03209323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bispectral index (BIS)
Description: The BIS score was derived from a sensor (Aspect Medical Systems) positioned diagonally on the patients' foreheads according to producer's instructions.
Study NCT03209323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: response and state entropy (RE and SE)
Description: The respone and state entropy (RE and SE) score was derived from a sensor (Aspect Medical Systems) positioned diagonally on the patients' foreheads according to producer's instructions.
Study NCT03209323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: middle latency auditory evoked potentials (MLAEP)
Description: value of A-line Auto Regressive Index (AAI) derived from middle latency auditory evoked potentials (MLAEP) (A-line Monitor, Danmeter A/S, Odense, Denmark) was observed which measures the central nervous system responsiveness to a specific auditory stimulus
Study NCT03353064 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vivify
Description: A telemedicine kit will (Vivify) which will obtain daily biometrics (vital signs) and care plans. These are all monitored by the Pulmonary team remotely via an online portal. The telemedicine system has a set-up for alerts whenever there are clinical concerns (vital signs out of parameters), or non-use of the Non-invasive positive pressure ventilation (NIPPV). This system allows for video conferencing between the Pulmonary team (physician, respiratory therapist, nurse) to troubleshoot issues, and increase NIPPV compliance.
Study NCT03353064 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EMS
Description: Emergency medical service scheduled home visits for face to face troubleshooting of the NIPPV, environmental check and end-tidal CO2.
Study NCT01292551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosentan
Description: tablets Bosentan 62,5 mg x 2 daily for two weeks, then 125 mg x 2 daily for 12 weeks
Study NCT01292551 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets 2 x daily for 2 weeks, then change to different placebo tablets to match Bosentan group, 2 x daily for 12 weeks
Study NCT02342886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral
Study NCT02342886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: Oral
Study NCT02342886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Oral
Study NCT02342886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)
Description: Oral
Study NCT02342886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HR (rifampicin plus isoniazid combination tablets)
Description: Oral
Study NCT01064297 — intervention group
Intervention type: DRUG
Intervention: Lamotrigine monotherapy
Description: Lamotrigine monotherapy
Study NCT01064297 — intervention group
Intervention type: DRUG
Intervention: Lamotrigine polytherapy including valproate
Description: Lamotrigine polytherapy including valproate
Study NCT01064297 — intervention group
Intervention type: DRUG
Intervention: Lamotrigine polytherapy without valproate
Description: Lamotrigine polytherapy without valproate
Study NCT00045305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Immunosuppressant
Study NCT00045305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Antimetabolite
Study NCT00045305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photopheresis
Description: Psoralens
Study NCT00045305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycofenolate mofetil
Description: an antibiotic with immunosuppressamt properties isolated from Penicillium spp
Study NCT00045305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Purine analogue
Study NCT00045305 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow
Description: Unmanipulated allogeneic bone marrow
Study NCT00045305 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell
Description: G-CSF mobilized peripheral blood stem cell
Study NCT00045305 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: a total of 600 cGy given in 3 200 cGy fractionated doses
Study NCT00361439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone
Description: 2 puffs in each nostril once daily of nasal spray
Study NCT00361439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 puffs in each nostril once daily of nasal spray
Study NCT01426971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBUPROFEN + CAFFEINE
Description: Pharmaceutical form: capsule Route of administration: oral
Study NCT01426971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IBUPROFEN
Description: Pharmaceutical form: capsule Route of administration: oral
Study NCT02259738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Urinary Kallidinogenase
Study NCT02259738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shuxuening injection
Study NCT04370925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical colectomy
Description: Patients undergo radical resection of the primary colorectal cancer(open or laparoscopic/robotic)
Study NCT04370925 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical colectomy
Description: Patients undergo radical resection of the primary colorectal cancer(open or laparoscopic/robotic)
Study NCT04370925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: HIPEC(simultaneously or within 2days after resection) with mitomycin c (30 mg/m2) at 43°C for 90 minutes.
Study NCT04370925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy
Description: Systemic chemotherapy regimens: CapeOx and mFOLFOX6 are preferred for stage Ⅲ patients.~CapeOx:oxaliplatin 130 mg/m2 IV d1 + capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.~mFOLFOX6:oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~For stageⅡpatiens, regimens recommend by NCCN guide line(2019 v1) are acceptable.
Study NCT04370925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic chemotherapy
Description: Systemic chemotherapy regimens: CapeOx and mFOLFOX6 are preferred for stage Ⅲ patients.~CapeOx:oxaliplatin 130 mg/m2 IV d1 + capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.~mFOLFOX6:oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~For stageⅡpatiens, regimens recommend by NCCN guide line(2019 v1) are acceptable.
Study NCT00140205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-metHuLeptin
Description: r-metreleptin was given in 3 different dose in fed and fasting states
Study NCT01353781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: Patients will be given AZD5363 capsules administered orally as a single dose, and then multiple twice-daily dosing following 3 to 7 days washout.
Study NCT03427684 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypo-fractionated radiotherapy
Description: Hypo-fractionated radiotherapy with fraction >2Gy .
Study NCT03427684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S-1 80mg/m2/day, orally intake on radiotherapy days.
Study NCT03859882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: 40 hours of continuous awaking in the sleep laboratory in order to compare before and after sleep deprivation for each treatment (Caffeine vs. placebo).
Study NCT03859882 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sleep deprivation
Description: 40 hours of continuous awaking in the sleep laboratory in order to compare before and after sleep deprivation for each treatment (Caffeine vs. placebo).
Study NCT04859634 — intervention group
Intervention type: DEVICE
Intervention: Taking an ultra-widefield fundus image
Description: The participant only needs to take an ultra-widefield fundus image as usual.
Study NCT04126408 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: gammaCore
Description: The intervention consists of a transcutaneous non-invasive stimulation of the cervical branch of the vagus nerve (nVNS) using gammaCore, an FDA approved device for the treatment of migraine and cluster headache. This will be compared to the sham device, which is the same device which will not provide stimulation to the nerve. Stimulation frequency will be identical to the frequency used in previous nVNS studies for the treatment of migraine headache.
Study NCT04126408 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gammaCore
Description: The intervention consists of a transcutaneous non-invasive stimulation of the cervical branch of the vagus nerve (nVNS) using gammaCore, an FDA approved device for the treatment of migraine and cluster headache. This will be compared to the sham device, which is the same device which will not provide stimulation to the nerve. Stimulation frequency will be identical to the frequency used in previous nVNS studies for the treatment of migraine headache.
Study NCT00770926 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Live Well, Be Well
Description: Lifestyle change program using personal contact and telephone counseling
Study NCT02836223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interdental cleaning device
Description: Water Flosser
Study NCT02836223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Tooth brush
Description: Control
Study NCT02836223 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Manual Tooth brush
Description: Control
Study NCT00168038 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunoglobulin Intravenous (Human)
Description: A dose of 1 g IgG per kg body weight (bw) administered on two consecutive days resulting in the total treatment dosage of 2 g IgG per kg bw.
Study NCT01274052 — intervention group
Intervention type: OTHER
Intervention: Meal test
Description: Liquid meal test
Study NCT01938248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: apixaban at a dose of 5 mg twice daily (2.5 mg twice daily if 2 or more of: age > 80, weight ≤ 60 kg or serum creatinine ≥ 133 mmol/L)
Study NCT01938248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: aspirin 81 mg once daily
Study NCT04841941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G4 Multifocal soft contact lens with a 54% water content for presbyopia
Description: The participants must agree to wear lenses from a trial set with the fit assessed according to the Fitting Guide. Prescription lenses will then be ordered from the manufacturer.
Study NCT01602406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LJM716
Description: LJM716